Skip to main content
SpringerLink
Log in

Tumor necrosis factor α modifies resistance to interferon α in vivo: First clinical data

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

Patients with Philadelphia-positive chronic-phase chronic myelogenous leukemia (CML) resistant to interferon (IFN) α were treated in a phase I/II study with recombinant human tumor necrosis factor α to overcome IFNα resistance. Doses of 40, 80, 120 or 160 µg/m2 TNFα were given as 2-h infusions on 5 consecutive days every 3 weeks. IFNα (4 × 106 IU/m2 s.c., daily) treatment was continued. Six patients were treated, completing 1–24 (median, 12) treatment cycles. Five of the six patients achieved partial hematological remission, while the remaining patient had to stop treatment because of WHO grade 4 thrombocytopenia following the first TNFα cycle. No complete hematologic remission or cytogenetic improvement was seen. Side-effects were similar to those described for both substances alone. Maximum tolerable TNF doses usually varied between 80 µg/m2 and 160 µg/m2. To examine possible pathways of TNF activity in these patients, interferon receptor status and (2′–5′)-oligoadenylate synthetase levels were examined in peripheral blood mononuclear cells. Both parameters remained unchanged during TNFα treatment. These preliminary data point to significant clinical efficacy of additionally applyed TNFα in IFNα-resistant CML patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alimena G, Morra E, Lazzarino M, Liberata AM, Montefusco E, Inverardi D, Bernasconi P, Mancini M, Donti E, Grignani F, Bernasconi C, Dianzani F, Mandelli F (1988) Interferon alpha-2b therapy for Ph′-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 72: 642

    Google Scholar 

  2. Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA, Tavernier J, Fiers W (1986) Human tumour xenografts treated with recombinant human tumor necrosis factor alone or in combinations with interferons. Cancer Res 46: 3990

    Google Scholar 

  3. Bolton AE, Hunter WM (1974) The labeling of proteins to high specific activities by conjugation to a125I-containing alkylating agent: application to the radioimmunoassay. Biochem J 133: 529

    Google Scholar 

  4. Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS, Starnes HF, Sherwin SA, Old LJ, Oettgen HF (1987) Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 5: 1942

    Google Scholar 

  5. Clauss IM, Vandenplas B, Wathelet MG, Dorval C, Delforge A, Content J, Stryckmans P, Huez GA (1990) Analysis of interferon-inducible genes in cells of chronic myeloid leukemia patients responsive or resistant to an interferon-α treatment. Blood 76: 2337

    Google Scholar 

  6. Creaven PJ, Plager JE, Dupere S, Huben RP, Takita H, Mittelman A, Proefrock A (1987) Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 20: 137

    Google Scholar 

  7. deMel WCP, Hoffbrand AV, Giles FJ, Goldstone AH, Mehta AB, Ganeshaguru K (1990) Alpha interferon therapy for haematological malignancies: correlation between in vivo induction of the 2′,5′-oligoadenylate system and clinical response. Br J Haematol 74: 452

    Google Scholar 

  8. Demetri GD, Spriggs DR, Sherman ML, Arthur KA, Imamura K, Kufe DW (1989) A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo. J Clin Oncol 7: 1545

    Google Scholar 

  9. Jakubowski AA, Casper ES, Gabrilove JL, Templeton MA, Sherwin SA, Oettgen HF (1989) Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer. J Clin Oncol 7: 298

    Google Scholar 

  10. Kasid A, Director EP, Rosenberg SA (1989) Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. J Immunol 143: 736

    Google Scholar 

  11. Kloke O, Niederle N (1990) Development and mechanisms of interferon resistance. Cancer Treat Rev 17 [Suppl A]: 81

    Google Scholar 

  12. Kloke O, Moritz T, Matika S, Kummer G, Niederle N (1988) Reversal of resistance to interferon alfa by the addition of tumor necrosis factor: preclinical and clinical observations. Blut 57: 223

    Google Scholar 

  13. Langer JA, Pestka S (1986) Procedures for studying binding of interferon to human cells in suspension cultures. Methods Enzymol 119: 305

    Google Scholar 

  14. Merlin G, Revel M, Wallach D (1981) The interferon-induced enzyme oligo-isoadenylate synthetase: rapid determination of its in vitro products. Anal Biochem 110: 190

    Google Scholar 

  15. Moritz T, Niederle N, Baumann J, May D, Kurschel E, Osieka R, Kempeni J, Schlick E, Schmidt CG (1989) Phase I study of recombinant human tumor necrosis factor α in advanced malignant disease. Cancer Immunol Immunother 29: 144

    Google Scholar 

  16. Moritz T, Weissmann B, Grünewald B, Hust H, Kummer G, Niederle N (1992) Induction of 2′–5′oligoadenylate synthetase during interferon treatment of chronic myelogenous leukemia. Mol Biother 4: 97

    Google Scholar 

  17. Munson PJ, Rodbard D (1980) Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107: 220

    Google Scholar 

  18. Nagel-Hiemke M, Hiemke C, Kummer K, Moritz T, Müller H, Niederle N (1990) Mechanisms involved in the increase of leukocyte counts following tumor necrosis factor (TNF) administration in patients with chronic myelogenous leukemia (CML). Blut 61: 192

    Google Scholar 

  19. Nedwin GE, Svedersky LP, Bringham TS, Palladino MA, Goeddel DV (1985) Effect of interleukin 2, interferon-gamma and mitogens on the production of tumor necrosis factors alfa and beta. J Immunol 135: 2493

    Google Scholar 

  20. Niederle N, Kloke O, Osieka R, Wandl UB, Opalka B, Schmidt CG (1987) Interferon alfa-2b in the treatment of chronic myelogenous leukemia. Semin Oncol 14 [Suppl 2]: 29

    Google Scholar 

  21. Niederle N, Moritz T, Kloke O, Wandl U, May D, Becher R, Franz T, Opalka B, Seeber S (1991) Interferon alpha-2b in acute and chronic phase CML: initial response and long-term results in 54 patients. Eur J Cancer 27 [Suppl 4]: 7

    Google Scholar 

  22. Opalka B, Wandl UB, Becher B, Kloke O, Nagel-Hiemke M, Moritz T, Beer U, Seeber S, Niederle N (1991) Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon-gamma. Blood 78: 2188

    Google Scholar 

  23. Otto U, Conrad S, Schneider AW, Kempeni J, Schlick E, Klosterhalfen H (1990) Combined therapy with TNFα and α-2b-interferon: apromising approach to metastatic renal cell carcinoma. J Cancer Res Clin Oncol 116 [Suppl II]: 1057

    Google Scholar 

  24. Retsas S, Leslie M, Bottomley D (1989) Intralesional tumour necrosis factor combined with interferon gamma in metastatic melanoma. Br Med J 298: 1290

    Google Scholar 

  25. Rosenblum MG, Maxwell BL, Talpaz M, Kelleher PJ, McCredie KB, Gutterman JU (1986) In vivo sensitivity and resistance of chronic myelogenous leukemia cells to α-interferon: correlation with receptor binding and induction of 2′,5′-oligoadenylate synthetase. Cancer Res 46: 4848

    Google Scholar 

  26. Stella CC, Cazzola M, Ganser A, Dezza L, Völkers B, Ascari E (1987) Human recombinant tumor necrosis factor alpha (TNF-alpha) inhibits the growth of hemopoietic progenitor cells from chronic myelogenous leukemia. Immunobiology 175: 73

    Google Scholar 

  27. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU (1983) Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62: 689

    Google Scholar 

  28. Talpaz M, Kantarjian HM, McCredie KB, Trujillo JM, Keating MJ, Gutterman JU (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha-A in chronic myelogenous leukemia. N Engl J Med 314: 1065

    Google Scholar 

  29. Trinchieri G, Kobayashi M, Rosen M, Loudon R, Murphy M, Perussia B (1986) Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon. J Exp Med 164: 1206

    Google Scholar 

  30. Wiedenmann B, Reichardt P, Räth U, Theilmann L, Schüle B, Ho AD, Schlick E, Kempeni J, Hunstein W, Kommerell B (1989) Phase-I trial of intravenous infusion of tumor necrosis factor in advanced metastatic carcinomas. J Cancer Res Clin Oncol 115: 189

    Google Scholar 

  31. Williamson BD, Carswell EA, Rubin BY, Prendergast JS, Old LJ (1983) Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA 80: 5397

    Google Scholar 

  32. Wong GHW, Goeddel DV (1986) Tumour necrosis factors α and β inhibit virus replication and synergise with gamma interferon. Nature 323: 819

    Google Scholar 

  33. von Wussow P, Hartmann F, Freund M, Poliwoda H, Deicher H (1988) Successful treatment of rIFN-α2b-antibody positive patients with natural IFN-α. Lancet 1: 882

    Google Scholar 

  34. Yoffe G, Blick M, Kantarjian HM (1987) Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia. Blood 69: 961

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), University of Essen, Germany

    Thomas Moritz, Otto Kloke, Marianne Nagel-Hiemke, Gerd Kummer, Ursula B. Wandl, Birgit Plappert & Siegfried Seeber

  2. Institut für Molekularbiologie, University of Essen, Germany

    Bertram Opalka

  3. Knoll AG, Ludwigshafen, Germany

    Joachim Kempeni

  4. Innere Klinik III, Städtisches Krankenhaus, Leverkusen, Germany

    Norbert Niederle

Authors
  1. Thomas Moritz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Otto Kloke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marianne Nagel-Hiemke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gerd Kummer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ursula B. Wandl
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bertram Opalka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Birgit Plappert
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Joachim Kempeni
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Siegfried Seeber
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Norbert Niederle
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moritz, T., Kloke, O., Nagel-Hiemke, M. et al. Tumor necrosis factor α modifies resistance to interferon α in vivo: First clinical data. Cancer Immunol Immunother 35, 342–346 (1992). https://doi.org/10.1007/BF01741148

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01741148

Key words

Search

Navigation